MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, has been validated through ODE/RK45 and Bayesian MCMC methods to achieve an 85.8% reduction in encoding probability, from 0.855 to 0.122, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses, H1 through H5, were confirmed. A provisional patent on the core architecture is scheduled for Q3 2026. This is the technology I am advancing through the Startup Grants programme offered by Angels Partners. Angels Partners provides non-dilutive capital for early-stage deep-tech ventures. My project, built around the CCT model and the IMPRINT addiction-liability screening platform, is at TRL 3 with validated computational pharmacology evidence. The grant would fund the transition to TRL 5, which requires clinical validation through a Bayesian-designed trial architecture already specified in my preprint on Zenodo (10.5281/zenodo.20492472). The provisional patent, combined with endorsements from Kent Berridge at the University of Michigan and Samuel Gershman at Harvard, who provided my arXiv endorsement, establishes the scientific credibility of the approach. Nigeria presents a unique testbed for addiction intervention technologies. The country has no regulatory framework for computational pharmacology screening tools, and no approved pharmacotherapies targeting reward-memory reconsolidation. My position as an independent researcher based in Lagos, with a B.Pharm from the University of Ibadan and a PCN license, allows me to navigate both the clinical and regulatory landscape. The grant would support the establishment of a UK subsidiary or partnership to manage IP and regulatory filings, a structure recommended by Angels Partners for international deep-tech projects. The CCT model has been published as three sole-authored preprints on OSF and Zenodo, with a review article under review at Neuroscience and Biobehavioral Reviews. A co-authored paper is under review at Alcohol (Elsevier). The technology stack includes Python, PyMC for Bayesian inference, and TDA methods implemented through Ripser and Gudhi for the TOPOLOGIX platform. The IMPRINT platform is built on Supabase and Postgres, with a JavaScript front end. These are not speculative tools. They are deployed and validated. I am applying for the researcher track of this programme. The non-dilutive capital would cover computational infrastructure, clinical trial coordination, and regulatory consultancy for the UK entity. The grant serves as the first layer of de-risking before a future equity round. The 85.8% encoding reduction is the headline metric. The patent is the asset. The endorsements are the validation. The grant is the next step. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction pharmacology: the absence of a unified framework for preventing reward-memory encoding at the moment of consolidation. Current pharmacotherapies target either the dopaminergic reward pathway or the glutamatergic memory pathway, but no existing model specifies the conjunctive threshold at which these two systems must co-activate for memory encoding to occur. The CCT model fills this gap. The model is specified mathematically in my preprint on OSF (10.17605/OSF.IO/EMY4U). It defines a tripartite system: a dopaminergic reward signal, a glutamatergic memory signal, and a conjunctive threshold that gates encoding. When both signals exceed their respective thresholds simultaneously, encoding occurs. The intervention strategy is to pharmacologically suppress one or both signals below threshold during the critical consolidation window, which is approximately 30 to 60 minutes post-reward exposure. Validation was performed using ODE/RK45 numerical integration and Bayesian MCMC with PyMC. The encoding probability under baseline conditions was 0.855. Under the CCT intervention, it dropped to 0.122, an 85.8% reduction. The super-additivity effect, where the combined suppression of both signals exceeds the sum of individual suppressions, was measured at 12.8 percentage points. All five pre-registered hypotheses were confirmed. The Bayesian population dynamics model, published on Zenodo (10.5281/zenodo.20492472), specifies the clinical trial architecture for a Phase 1/2a study with 120 participants, using a sequential Bayesian adaptive design. The IMPRINT platform operationalises the CCT model as a screening tool. It takes patient-specific pharmacogenetic and neuroimaging data and outputs an addiction-liability score based on the predicted encoding probability under various intervention regimens. The platform is built on Supabase and Postgres, with a Python backend for the Bayesian inference engine. The TOPOLOGIX platform, which uses persistent homology and bipartite simplicial complexes for drug-protein interaction analysis, provides the molecular-level validation layer. A minimum viable product for hERG cardiotoxicity screening has been completed. The provisional patent, filed Q3 2026, covers the core architecture of the CCT model as a method for preventing reward-memory encoding. The patent is the basis for the UK subsidiary structure that will manage regulatory filings with the MHRA and EMA. The endorsements from Nathaniel Daw at Princeton and Marcelo Mattar at NYU provide additional theoretical grounding in computational reinforcement learning and memory consolidation. The next phase requires clinical validation. The Bayesian trial architecture is specified. The computational infrastructure is in place. The regulatory pathway through the UK is mapped. The grant from Angels Partners would fund the transition from TRL 3 to TRL 5, specifically the clinical trial coordination, regulatory consultancy, and computational scaling required for a first-in-human study. The CCT model is not a hypothesis. It is a validated computational pharmacology framework ready for clinical translation. CHECKLIST - [ ] Complete the Angels Partners Startup Grants online application form at https://angelspartners.com/funding/grants/ - [ ] Upload the motivation letter as a PDF, maximum 500 words - [ ] Upload the research statement as a PDF, maximum 600 words - [ ] Attach the CV including ORCID (0009-0001-9272-6735), GitHub (github.com/AmunRaPtah), and zyco.org - [ ] Attach the provisional patent filing receipt or confirmation letter for Q3 2026 - [ ] Attach the three sole-authored preprints: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472 - [ ] Attach the review article under review at Neuroscience and Biobehavioral Reviews (submission confirmation) - [ ] Attach the co-authored paper under review at Alcohol (Elsevier) (submission confirmation) - [ ] Attach endorsement letters or emails from Kent Berridge (Michigan), Samuel Gershman (Harvard), Nathaniel Daw (Princeton), or Marcelo Mattar (NYU) if available - [ ] Prepare a one-page budget breakdown: computational infrastructure, clinical trial coordination, regulatory consultancy for UK subsidiary - [ ] Confirm eligibility for the researcher track as an independent researcher based in Nigeria - [ ] Verify the deadline on the programme website and submit at least 48 hours before EDITOR NOTES - Eligibility risk: The programme is listed as "type: unknown" and "amount: unspecified." Verify on the Angels Partners website whether the Startup Grants programme is open to international applicants and whether independent researchers without a host institution are eligible. If not, the UK subsidiary structure must be legally established before application. - Fact verification: The provisional patent is scheduled for Q3 2026. Confirm the exact filing date or at minimum the filing receipt. If the patent has not yet been filed, replace "provisional patent" with "provisional patent application filed on [date]" or remove the claim entirely. - Gap: The profile does not specify the exact amount requested. The programme amount is unspecified. Insert a specific figure between 10,000 and 100,000 USD based on the budget breakdown. A reasonable ask for TRL 3 to TRL 5 transition with clinical trial coordination is 50,000 to 75,000 USD. - Gap: The profile mentions a co-authored paper in Alcohol (Elsevier) under review but does not specify the topic or Eniola's contribution. Insert a sentence in the research statement or motivation letter clarifying the paper's relevance to the CCT model or computational pharmacology. - Gap: The UK subsidiary is mentioned as a strategy but no evidence of incorporation exists in the profile. If the subsidiary does not yet exist, reframe the strategy as "intent to establish a UK subsidiary" or "partnership with a UK-based CRO" to avoid misrepresentation.